PSMA-PET/MRI for Radiation Treatment Planning in Patients with Locally Metastatic Prostate Cancer

This phase I trial studies the feasibility of using gallium Ga 68 gozetotide (PSMA)-positron emission tomography (PET)/magnetic resonance imaging (MRI) for radiation treatment planning in patients with prostate cancer that has spread to the pelvis (locally metastatic). Gallium Ga 68 gozetotide binds to a protein called prostate-specific membrane antigen (PSMA) located on prostate cells. Prostate cancer cells have higher levels of PSMA protein and take up more [68Ga]PSMA-11 than normal cells allowing scientist to see or image the cancer cells using positron emission tomography (PET). PET is a type of scan that uses a small amount of injected radioactive drug to see how cells or tissues are working. PET can be added to a MRI machine which uses magnetic fields and radio waves to make pictures of the inside of your body. PSMA-PET/MRI may be more useful for guiding the radiation treatment plan than MRI alone.

Additional locations may be listed on ClinicalTrials.gov for NCT04086966.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase I

Trial Typediagnostic

Lead OrganizationUniversity of Alabama at Birmingham Cancer Center

Principal InvestigatorSamuel Galgano

• Primary IDUAB1943
• Secondary IDsNCI-2021-03550
• ClinicalTrials.gov IDNCT04086966